Gelsolin as therapeutic target in Alzheimer's disease

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 6, 2010, Pages 585-592

  Carro, Eva ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Alzheimer's disease; Apoptosis; Central nervous system; Choroid plexus; Gelsolin

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; GELSOLIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROSTAGLANDIN SYNTHASE;

ACTIN FILAMENT; ACTIN POLYMERIZATION; ALZHEIMER DISEASE; APOPTOSIS; BRAIN FUNCTION; BRAIN LEVEL; CELL LOSS; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; NERVE CELL; NERVE CELL NECROSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIOXIDANTS; APOPTOSIS; BRAIN; DRUG DELIVERY SYSTEMS; GELSOLIN; HUMANS;

EID: 77952256597     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2010.488222     Document Type: Review

References (100)

1. Golde TE. Alzheimer disease therapy: can the amyloid cascade be halted? J Clin Invest 2003;111:11-8
2. Selkoe DJ. The deposition of amyloid proteins in the aging mammalian brain: implications for Alzheimer's disease. Ann Med 1989;14:73-6
3. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416:535-9
4. D'Amore JD, Kajdasz ST, McLellan ME, et al. In vivo multiphoton imaging of a transgenic mouse model of Alzheimer disease reveals marked thioflavine-S-associated alterations in neurite trajectories. J Neuropathol Exp Neurol 2003;62:137-45
5. Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001;293:1487-91
6. Oddo S, Billings L, Kesslak JP, et al. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004;43:321-32
7. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991;6:487-98
8. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-5
9. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-6
10. Selkoe DJ. Alzheimer's disease. In the beginning. Nature 1991;354:432-3
11. Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron 2001;32:177-80
12. Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007;316:750-4
13. Wisniewski T, Ghiso J, Frangione B. Biology of Abeta amyloid in Alzheimer's disease. Neurobiol Dis 1997;4:313-8
14. Davies TA, Long HJ, Eisenhauer PB, et al. beta amyloid fragments derived from activated platelets deposit in cerebrovascular endothelium: usage of a novel blood brain barrier endothelial cell model system. Amyloid 2000;7:153-65
15. Dietrich MO, Spuch C, Antequera D, et al. Megalin mediates the transport of leptin across the blood-CSF barrier. Neurobiol Aging 2008;29:902-12
16. Vargas T, Ugalde C, Spuch C, et al. Abeta accumulation in choroid plexus is associated with mitochondrial-induced apoptosis. Neurobiol Aging 2008; 4. [Epub ahead of print]
17. Perez-Gracia E, Blanco R, Carmona M, et al. Oxidative stress damage and oxidative stress responses in the choroid plexus in Alzheimer's disease. Acta Neuropathol 2009;118:497-504
18. Rubin LL, Staddon JM. The cell biology of the blood-brain barrier. Annu Rev Neurosci 1999;22:11-28
19. Koya RC, Fujita H, Shimizu S, et al. Gelsolin inhibits apoptosis by blocking mitochondrial membrane potential loss and cytochrome c release. J Biol Chem 2000;275:15343-9
20. Qiao H, Koya RC, Nakagawa K, et al. Inhibition of Alzheimer's amyloid-beta peptide-induced reduction of mitochondrial membrane potential and neurotoxicity by gelsolin. Neurobiol Aging 2005;26:849-55
21. Sun HQ, Yamamoto M, Mejillano M, Yin HL. Gelsolin, a multifunctional actin regulatory protein. J Biol Chem 1999;274:33179-82
22. Cunningham CC, Stossel TP, Kwiatkowski DJ. Enhanced motility in NIH 3T3 fibroblasts that overexpress gelsolin. Science 1991;251:233-6
23. Witke W, Sharpe AH, Hartwig JH, et al. Hemostatic, inflammatory, and fibroblast responses are blunted in mice lacking gelsolin. Cell 1995;81:41-51
24. Ohtsu M, Sakai N, Fujita H, et al. Inhibition of apoptosis by the actin-regulatory protein gelsolin. EMBO J 1997;16:4650-6
25. Kamada S, Kusano H, Fujita H, et al. A cloning method for caspase substrates that uses the yeast two-hybrid system: cloning of the antiapoptotic gene gelsolin. Proc Natl Acad Sci USA 1998;95:8532-7
26. Kothakota S, Azuma T, Reinhard C, et al. Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 1997;278:294-8
27. Antequera D, Vargas T, Ugalde C, et al. Cytoplasmic gelsolin increases mitochondrial activity and reduces Abeta burden in a mouse model of Alzheimer's disease. Neurobiol Dis 2009;36:42-50
28. Kwiatkowski DJ. Functions of gelsolin: motility, signaling, apoptosis, cancer. Curr Opin Cell Biol 1999;11:103-8
29. Liu YT, Yin HL. Identification of the binding partners for flightless I, A novel protein bridging the leucine-rich repeat and the gelsolin superfamilies. J Biol Chem 1998;273:7920-7
30. Burtnick LD, Koepf EK, Grimes J, et al. The crystal structure of plasma gelsolin: implications for actin severing, capping, and nucleation. Cell 1997;90:661-70
31. Kwiatkowski DJ, Stossel TP, Orkin SH, et al. Plasma and cytoplasmic gelsolins are encoded by a single gene and contain a duplicated actin-binding domain. Nature 1986;323:455-8
32. Bretscher A, Weber K. Villin is a major protein of the microvillus cytoskeleton which binds both G and F actin in a calcium-dependent manner. Cell 1980;20:839-47
33. de Couet HG, Fong KS, Weeds AG, et al. Molecular and mutational analysis of a gelsolin-family member encoded by the flightless I gene of Drosophila melanogaster. Genetics 1995;141:1049-59
34. Marks PW, Arai M, Bandura JL, Kwiatkowski DJ. Advillin (p92) : a new member of the gelsolin/villin family of actin regulatory proteins. J Cell Sci 1998;111:2129-36
35. Pestonjamasp KN, Pope RK, Wulfkuhle JD, Luna EJ. Supervillin (p205) : a novel membrane-associated, F-actin-binding protein in the villin/gelsolin superfamily. J Cell Biol 1997;139:1255-69
36. Robbens J, Louahed J, De Pestel K, et al. Murine adseverin (D5), a novel member of the gelsolin family, and murine adseverin are induced by interleukin-9 in T-helper lymphocytes. Mol Cell Biol 1998;18:4589-96
37. Sakurai T, Kurokawa H, Nonomura Y. Comparison between the gelsolin and adseverin domain structure. J Biol Chem 1991;266:15979-83
38. Dabiri GA, Young CL, Rosenbloom J, Southwick FS. Molecular cloning of human macrophage capping protein cDNA. A unique member of the gelsolin/villin family expressed primarily in macrophages. J Biol Chem 1992;267:16545-52
39. Yu FX, Johnston PA, Südhof TC, Yin HL. gCap39, a calcium ion-and polyphosphoinositide-regulated actin capping protein. Science 1990;250:1413-5
40. Kwiatkowski DJ, Mehl R, Yin HL. Genomic organization and biosynthesis of secreted and cytoplasmic forms of gelsolin. J Cell Biol 1988;106:375-84
41. Stossel TP. Actin-membrane interactions in eukaryotic mammalian cells. In: Hoffman JF, Giebisch G, editors, Current topics in membranes and transport. Academic Press, New York; 1990. p. 97-107
42. Chauhan VP, Ray I, Chauhan A, Wisniewski HM. Binding of gelsolin, a secretory protein, to amyloid beta-protein. Biochem Biophys Res Commun 1999;258:241-6
43. Matsumoto N, Kitayama H, Kitada M, et al. Isolation of a set of genes expressed in the choroid plexus of the mouse using suppression subtractive hybridization. Neuroscience 2003;117:405-15
44. Janmey PA, Stossel TP. Modulation of gelsolin function by phosphatidylinositol 4, 5-biphosphate. Nature 1987;325:362-4
45. Kwiatkowski DJ, Janmey PA, Yin HL. Identification of critical functional and regulatory domains in gelsolin. J Cell Biol 1989;108:1717-26
46. Azuma T, Witke W, Stossel TP, et al. Gelsolin is a downstream effector of rac for fibroblast motility. EMBO J 1998;17:1362-79
47. Tanaka J, Sobue K. Localization and characterization of gelsolin in nervous tissues: gelsolin is specifically enriched in myelin-forming cells. J Neurosci 1994;14:1038-52
48. Roth LW, Bormann P, Wiederkehr C, Reinhard E. beta-thymosin, a modulator of the actin cytoskeleton is increased in regenerating retinal ganglion cells. Eur J Neurosci 1999;11:3488-98
49. Dong JH, Ying GX, Liu X, et al. Lesion-induced gelsolin upregulation in the hippocampus following entorhinal deafferentation. Hippocampus 2006;16:91-100
50. Vouyiouklis DA, Brophy PJ. A novel gelsolin isoform expressed by oligodendrocytes in the central nervous system. J Neurochem 1997;69:995-1005
51. Endres M, Fink K, Zhu J, et al. Neuroprotective effects of gelsolin during murine stroke. J Clin Invest 1999;103:347-54
52. Zipfel GJ, Babcock DJ, Lee JM, Choi DW. Neuronal apoptosis after CNS injury: the roles of glutamate and calcium. J Neurotrauma 2000;17:857-69
53. Matus A. Actin-based plasticity in dendritic spines. Science 2000;290:754-8
54. Halpain S, Hipolito A, Saffer L. Regulation of F-actin stability in dendritic spines by glutamate receptors and calcineurin. J Neurosci 1998;18:9835-44
55. Rao A, Craig AM. Signaling between the actin cytoskeleton and the postsynaptic density of dendritic spines. Hippocampus 2000;10:527-41
56. Star EN, Kwiatkowski DJ, Murthy VN. Rapid turnover of actin in dendritic spines and its regulation by activity. Nat Neurosci 2002;5:239-46
57. McGrath JL, Osborn EA, Tardy YS, et al. Regulation of the actin cycle in vivo by actin filament severing. Proc Natl Acad Sci USA 2000;97:6532-7
58. Chauhan V, Ji L, Chauhan A. Anti-amyloidogenic, anti-oxidant and anti-apoptotic role of gelsolin in Alzheimer's disease. Biogerontology 2008;9:381-9
59. Kirkitadze MD, Kowalska A. Molecular mechanisms initiating amyloid beta-fibril formation in Alzheimer's disease. Acta Biochim Pol 2005;52:417-23
60. Tamagno E, Robino G, Obbili A, et al. H2O2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK. Exp Neurol 2003;180:144-55
61. Ji L, Chauhan A, Chauhan V. Cytoplasmic gelsolin in pheochromocytoma-12 cells forms a complex with amyloid beta-protein. Neuroreport 2008;19:463-6
62. Bosetti F, Brizzi F, Barogi S, et al. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol Aging 2002;23:371-6
63. Casley CS, Canevari L, Land JM, et al. beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activity. J Neurochem 2002;80:91-100
64. Devi L, Prabhu BM, Galati DF, et al. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J Neurosci 2006;26:9057-68
65. Fukui H, Diaz F, Garcia S, Moraes CT. Cytochrome c oxidase deficiency in neurons decreases both oxidative stress and amyloid formation in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2007;104:14163-8
66. Cardoso SM, Santana I, Swerdlow RH, Oliveira CR. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J Neurochem 2004;89:1417-26
67. Kish SJ, Bergeron C, Rajput A. Brain cytochrome oxidase in Alzheimer's disease. J Neurochem 1992;59:776-9
68. Mancuso M, Filosto M, Bosetti F, et al. Decreased platelet cytochrome c oxidase activity is accompanied by increased blood lactate concentration during exercise in patients with Alzheimer disease. Exp Neurol 2003;182:421-6
69. Aleardi AM, Benard G, Augereau O, et al. Gradual alteration of mitochondrial structure and function by beta-amyloids: importance of membrane viscosity changes, energy deprivation, reactive oxygen species production, and cytochrome c release. J Bioenerg Biomembr 2005;37:207-25
70. Smith MA, Richey Harris PL, Sayre LM, et al. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997;17:2653-7
71. Aliyev A, Seyidova D, Rzayev N, et al. Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease? Neurol Res 2004;26:547-53
72. Keil U, Bonert A, Marques CA, et al. Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J Biol Chem 2004;279:50310-20
73. Galkin A, Moncada S. S-nitrosation of mitochondrial complex I depends on its structural conformation. J Biol Chem 2007;282:37448-53
74. Galli S, Labato MI, Bal de Kier Joffé E, et al. Decreased mitochondrial nitric oxide synthase activity and hydrogen peroxide relate persistent tumoral proliferation to embryonic behaviour. Cancer Res 2003;63:6370-7
75. Carreras MC, Franco MC, Peralta JG, Poderoso JJ. Nitric oxide, complex I, and the modulation of mitochondrial reactive species in biology and disease. Mol Aspects Med 2004;25:125-39
76. Kusano H, Shimizu S, Koya RC, et al. Human gelsolin prevents apoptosis by inhibiting apoptotic mitochondrial changes via closing VDAC. Oncogene 2000;19:4807-14
77. Yankner BA, Dawes LR, Fisher S, et al. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 1989;245:417-20
78. Matsuoka Y, Saito M, LaFrancois J, et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 2003;23:29-33
79. Hirko AC, Meyer EM, King MA, Hughes JA. Peripheral transgene expression of plasma gelsolin reduces amyloid in transgenic mouse models of Alzheimer's disease. Mol Ther 2007;15:1623-9
80. Vargas T, Antequeral D, Ugalde C, et al. Gelsolin restores Ab-induced alterations in choroid plexus epithelium. J Biomed Biotech 2010; 2010: Article ID 805405
81. Ray I, Chauhan A, Wegiel J, Chauhan VP. Gelsolin inhibits the fibrillization of amyloid beta-protein, and also defibrillizes its preformed fibrils. Brain Res 2000;853:344-51
82. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002;298:789-91
83. Jacobsen JS, Wu CC, Redwine JM, et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2006;103:5161-6
84. Wu CC, Chawla F, Games D, et al. Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: digital morphometric analyses. Proc Natl Acad Sci USA 2004;101:7141-6
85. Small SA, Chawla MK, Buonocore M, et al. Imaging correlates of brain function in monkeys and rats isolates a hippocampal subregion differentially vulnerable to aging. Proc Natl Acad Sci USA 2004;101:7181-6
86. Scheff SW, Sparks DL, Price DA. Quantitative assessment of synaptic density in the outer molecular layer of the hippocampal dentate gyrus in Alzheimer's disease. Dementia 1996;7:226-32
87. Morrison JH, Hof PR. Life and death of neurons in the aging brain. Science 1997;278:412-9
88. Kim CH, Lisman JE. A role of actin filament in synaptic transmission and long-term potentiation. J Neurosci 1999;19:4314-24
89. Krucker T, Siggins GR, Halpain S. Dynamic actin filaments are required for stable long-term potentiation (LTP) in area CA1 of the hippocampus. Proc Natl Acad Sci USA 2000;97:6856-61
90. Zhou Q, Xiao MY, Nicoll RA. Contribution of cytoskeleton to the internalization of AMPA receptors. Proc Natl Acad Sci USA 2001;98:1261-6
91. Hartmann A. Antiapoptotic agents in brain ischemia. N Engl J Med 2000;342:823
92. Rao J. Targeting actin remodeling profiles for the detection and management of urothelial cancers-a perspective for bladder cancer research. Front Biosci 2002; 7: e1-8
93. Fujita H, Okada F, Hamada J, et al. Gelsolin functions as a metastasis suppressor in B16-BL6 mouse melanoma cells and requirement of the carboxyl-terminus for its effect. Int J Cancer 2001;93:773-80
94. Tanaka M, Mülauer L, Ogiso Y, et al. Gelsolin: a candidate for suppressor of human bladder cancer. Cancer Res 1995;55:3228-32
95. Tanaka M, Sazawa A, Shinohara N, et al. Gelsolin gene therapy by retrovirus producer cells for human bladder cancer in nude mice. Cancer Gene Ther 1999;6:482-7
96. Culver KW, Ram Z, Wallbridge S, et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992;256:1550-2
97. Takamiya Y, Short MP, Moolten FL, et al. An experimental model of retrovirus gene therapy for malignant brain tumors. J Neurosurg 1993;79:104-10
98. Izquierdo M, Cortes M, Felipe P, et al. Long-term rat survival after malignant brain tumor regression by retroviral gene therapy. Gene Ther 1995;2:66-9
99. Asch HL, Head K, Dong Y, et al. Widespread loss of gelsolin in breast cancers of humans, mice, and rats. Cancer Res 1996;56:4841-5
100. Dosaka-Akita H, Hommura F, Fujita H, et al. Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers. Cancer Res 1998;58:322-7